Commentary Second line treatment of small cell lung cancer: more is better? Michael S. Humeniuk, Michael John Kelley Abstract Extensive stage small cell lung cancer (SCLC) is an aggressive disease that leaves less than 10% of patients alive at 2 years (1).
